Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ...

For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to a study published online ...

Fatty liver disease is a growing global health concern. Proglucagon-derived peptides (PGDPs), including glucagon, GLP-1, and GLP-2, are known to regulate lipid metabolism in the liver. However ...

Jennifer Linge, PhD https://orcid.org/0000-0001-7399-8375 AMRA Medical AB, Linköping, Sweden (J.L.). Division of Diagnostics and Specialist Medicine, Department of ...

Dr. Patricia Brubaker has spent decades researching and speaking on studies relating to the development of the intestinal hormone glucagon-like peptide-1 (GLP-1) for the treatment of patients with ...

Another factor is the increased use of glucagon-like peptide-1 (GLP-1) drugs to treat obesity and Type 2 diabetes. The drugs, sold under brand names such as Wegovy and Ozempic, have become popular ...

The event will feature: What are GLP-1s (glucagon-like peptides) and how they work Who are candidates for these medications Maximizing results and minimizing potential side effects The importance ...

It also describes the various GLP-1s on the market and the differences between them. Glucagon-like peptide (GLP-1) is a type of hormone known as an incretin that's lower than normal in people with ...

Ozempic and its sister drug Wegovy lowers blood sugar levels and suppress glucose made in the liver causing a reaction in users that mimics GLP-1, or glucagon-like peptide-1, a hormone found in ...

Concerns over the glucagon-like peptide-1 (GLP-1) drugs currently leading the treatment of obesity and type 2 diabetes follow clinical studies that suggested patients lost muscle at far faster ...